Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/11793
Title: Auto-titrating continuous positive airway pressure treatment for obstructive sleep apnoea after acute quadriplegia (COSAQ): study protocol for a randomized controlled trial.
Authors: Berlowitz, David J;Ayas, Najib;Barnes, Maree;Brown, Douglas J;Cistulli, Peter A;Geraghty, Tim;Graham, Alison;Lee, Bonsan Bonne;Morris, Meg;O'Donoghue, Fergal J;Rochford, Peter D;Ross, Jack;Singhal, Balraj;Spong, Jo;Wadsworth, Brooke;Pierce, Robert J
Affiliation: david.berlowitz@austin.org.au
Institute for Breathing and Sleep, Austin Hospital, Melbourne, Australia
Issue Date: 19-Jun-2013
Citation: Trials 2013; 14(): 181
Abstract: Quadriplegia is a severe, catastrophic injury that predominantly affects people early in life, resulting in lifelong physical disability. Obstructive sleep apnoea is a direct consequence of quadriplegia and is associated with neurocognitive deficits, sleepiness and reduced quality of life. The usual treatment for sleep apnoea is nasal continuous positive airway pressure (CPAP); however, this is poorly tolerated in quadriplegia. To encourage patients to use this therapy, we have to demonstrate that the benefits outweigh the inconvenience. We therefore propose a prospective, multinational randomized controlled trial of three months of CPAP for obstructive sleep apnoea after acute quadriplegia.Specialist spinal cord injury centres across Australia, New Zealand, the UK and Canada will recruit medically stable individuals who have sustained a (new) traumatic quadriplegia (complete or incomplete second cervical to first thoracic level lesions). Participants will be screened for obstructive sleep apnoea using full, portable sleep studies. Those with an apnoea hypopnoea index greater than 10 per hour will proceed to an initial three-night trial of CPAP. Those who can tolerate CPAP for at least 4 hours on at least one night of the initial trial will be randomized to either usual care or a 3-month period of auto-titrating CPAP. The primary hypothesis is that nocturnal CPAP will improve neuropsychological functioning more than usual care alone. The secondary hypothesis is that the magnitude of improvement of neuropsychological function will be predicted by the severity of baseline sleepiness measures, sleep fragmentation and sleep apnoea. Neuropsychological tests and full polysomnography will be performed at baseline and 3 months with interim measures of sleepiness and symptoms of autonomic dysfunction measured weekly. Spirometry will be performed monthly. Neuropsychological tests will be administered by blinded assessors. Recruitment commenced in July 2009.The results of this trial will demonstrate the effect of nocturnal CPAP treatment of obstructive sleep apnoea in acute quadriplegia. If CPAP can improve neurocognitive function after injury, it is likely that rehabilitation and subsequent community participation will be substantially improved for this group of predominantly young and severely physically disabled people.Australian New Zealand Clinical Trial Registry ACTRN12605000799651.
Internal ID Number: 23777510
URI: http://ahro.austin.org.au/austinjspui/handle/1/11793
DOI: 10.1186/1745-6215-14-181
URL: http://www.ncbi.nlm.nih.gov/pubmed/23777510
Type: Journal Article
Subjects: Acute Disease
Australia
Autonomic Nervous System.physiopathology
Canada
Clinical Protocols
Continuous Positive Airway Pressure
Great Britain
Humans
Neuropsychological Tests
New Zealand
Polysomnography
Predictive Value of Tests
Prospective Studies
Quadriplegia.complications.physiopathology.psychology
Quality of Life
Questionnaires
Research Design
Sleep
Sleep Apnea, Obstructive.diagnosis.etiology.physiopathology.psychology.therapy
Spirometry
Time Factors
Treatment Outcome
Appears in Collections:Journal articles

Files in This Item:
File Description SizeFormat 
23777510.pdf311.96 kBAdobe PDFThumbnail
View/Open


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.